Abstract
ObjectivesTwo oral targeted therapies, gefitinib and erlotinib, were first approved and then launched into the market for treatment of late-stage non-small cell lung cancer (NSCLC) in Taiwan in 2003 and...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have